In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
News|Videos|June 11, 2019
Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL
Author(s)Jason Westin, MD
Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Advertisement
Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
3
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
4
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
5